← Back to Search

Mitochondrial-targeted antioxidant

MitoQ Supplementation for Cardiovascular Health

N/A

Waitlist Available

Led By Shauna Runchey, MD

Research Sponsored by University of Colorado, Denver

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

50 - 75 years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 4 weeks

Awards & highlights

Study Summary

This trial will see if an antioxidant called Mitoquinone can help improve mitochondrial function, heart function, and blood vessel function.

Who is the study for?

This trial is for healthy men and women aged 50-75 who are not very active, don't smoke, and aren't taking antioxidants, steroids or anti-inflammatory meds. They shouldn't have had cancer, cardiovascular disease or be on hormone therapy.Check my eligibility

What is being tested?

The study tests if MitoQ (a targeted antioxidant) can improve heart's mitochondrial function and blood vessel health in participants. They'll take MitoQ first then a placebo, or vice versa to compare effects.See study design

What are the potential side effects?

Potential side effects of MitoQ may include allergic reactions, gastrointestinal discomforts such as nausea or diarrhea, headache, fatigue but specific side effects will be monitored during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 75 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in diastolic function

Secondary outcome measures

Changes in arterial stiffness

Changes in arterial vascular coupling

Changes in brachial artery flow-mediated dilation

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: B: Placebo then 'MITOQUINOL MESYLATE'Experimental Treatment1 Intervention

Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'

Group II: A: 'MITOQUINOL MESYLATE then placeboExperimental Treatment1 Intervention

'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor

1,734 Previous Clinical Trials

2,148,852 Total Patients Enrolled

University of Colorado Nutrition Obesity Research Center (NORC)UNKNOWN

Shauna Runchey, MDPrincipal InvestigatorUniversity of Colorado, Denver

Media Library

Mitoquinone (MitoQ) (Mitochondrial-targeted antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT03586414 — N/A

Diastolic Dysfunction Research Study Groups: B: Placebo then 'MITOQUINOL MESYLATE', A: 'MITOQUINOL MESYLATE then placebo

Diastolic Dysfunction Clinical Trial 2023: Mitoquinone (MitoQ) Highlights & Side Effects. Trial Name: NCT03586414 — N/A

Mitoquinone (MitoQ) (Mitochondrial-targeted antioxidant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03586414 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research seeking to include elderly participants?

"Based on the trial guidelines, individuals between 50 and 75 years of age are eligible for enrollment."

Answered by AI

May I be considered for participation in this research project?

"To be eligible for this clinical trial, patients must suffer from diastolic dysfunction and fall within the age-range of 50 to 75 years old. A total of 60 individuals are required for inclusion in the study."

Answered by AI

Are there any vacancies in this clinical trial?

"Affirmative. The records on clinicaltrials.gov demonstrate that this trial, posted in August 2021 and last revised in August 2022 is actively looking for participants to join. Right now the plan is to enlist 60 subjects from only one centre."

Answered by AI

How many participants are actively involved in the current clinical research?

"Affirmative, the information available on clinicaltrials.gov reveals that this therapeutic experiment is actively seeking enrolment. It was first published on August 1st 2021 and has been amended lastly on August 22nd 2022; with a total of 60 individuals being sought at one facility."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women

2021. "MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03586414.

All > Cardiovascular